02:09 PM EDT, 10/02/2025 (MT Newswires) -- kneat.com ( KSIOF ) is a SaaS company, focused in Life Sciences but also gaining traction in the MedTech space, as evident by a new contract win for a U.S. domiciled company, notes Stifel Canada.

The contract is for computer systems validation and commissioning, qualification and validation at 18 manufacturing sites.

"We see the announcement as relatively material ARR of +$1mm over a three-year term with an opportunity to expand 2-4x, consistent with certain other customers," writes analyst Justin Keywood.

The win also highlights a record year of new customer logo adds, supporting solid ARR growth, last reported at +43% YoY to $65 million. Kneat's Net Retention Rate (NRR) is 151%, further demonstrating the 'land and expand' strategy works, Keywood adds.

"We believe upcoming high organic growth quarters (+30%), along with operating leverage, will bring attention to this pure-play SaaS company, leading to a higher share price."

Kneat has a Buy rating and $8.50 target.

Price: 5.84, Change: -0.10, Percent Change: -1.68